Case Report: Safety and Efficacy of Enfortumab Vedotin in a Patient With Metastatic Urothelial Carcinoma Undergoing Peritoneal Dialysis

The clinical management of metastatic urothelial carcinoma has significantly evolved with the emergence of monoclonal antibodies and antibody-drug conjugates (ADCs). Enfortumab vedotin (EV) was granted approval by the FDA in 2021 for patients with locally advanced or metastatic urothelial carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Collette, Kaylyn R., Myint, Zin W., Parasramka, Saurabh V., Ellis, Carleton S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174522/
https://www.ncbi.nlm.nih.gov/pubmed/35692805
http://dx.doi.org/10.3389/fonc.2022.892793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174522/
https://www.ncbi.nlm.nih.gov/pubmed/35692805
http://dx.doi.org/10.3389/fonc.2022.892793

Ejemplares similares